Inspection Record
View the regulator's official source The source document is always the basis for judgement.
The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).
The written procedures for recalls were inadequate.
The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
The ongoing stability program for a drug was inadequate.
The training of personnel in good manufacturing practices and/or the maintenance of records was inadequate.
The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.
Investigations into deviations, reports, and/or follow-up actions were inadequate.
The assessment to release finished products was inadequate.
Extracted automatically from the document of the Health Canada inspection on 2022-06-21. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
Growth stages previewSolve a quiz to start hatching
Your growth record is stored safely in this browser.
